- Bupa Platinum consultant
- Fee assured
- Verified account
- Open Referral network
Dr Jonathan Sive is an expert haematologist based in London. He specialises in the diagnosis and management of blood cancers, with particular expertise in the treatment of myeloma and other related disorders such as MGUS and plasmacytomas. He is the Clinical Service Lead for the UCLH myeloma service - the largest in the UK, and has a specialist interest in POEMS Syndrome.He is also highly experienced in the investigation of abnormal blood counts and paraproteins.
After qualifying, he completed specialist training in haematology at University College London Hospital and carried out a PhD at Cambridge University, where he investigated the use of genomic technologies to study the mechanisms of leukaemia development. He currently practises as a consultant haematologist at University College London Hospital, where he also has a private practice
Dr Sive is committed to research which improves treatment outcomes for all patients. In this respect, he is actively engaged in a variety of clinical research projects and takes a leading role in the development of national guidelines.
He is the lead author of the new UK national guidelines for the diagnosis and initial treatment of myeloma. These are published by the British Society for Haematology and the UK Myeloma Forum, and provide the standard for practice throughout the UK. https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.17410
His work has been widely published in numerous peer-reviewed journals and book chapters. He is also a member of the British Society for Haematology (BSH) and the UK Myeloma Research Alliance, and is member of the executive committee of the UK Myeloma Forum.
A skilled clinician, Dr Sive combines his academic expertise in blood disorders with dedication to delivering an excellent standard of care to every patient. He is known for his clear and empathetic communication style and will explore all treatment options relevant to the patient’s circumstances in an honest and sensitive manner.
Areas of interest
Haematological malignancy; myeloma; MGUS; general haematology (including investigation and management of paraproteins, anaemia, high and low white cell counts, neutropenia, high and low platelet counts, iron deficiency)
Current NHS consultant posts held
Clinical Service lead for Myeloma and Plasma Cell Disorders
University College London Hospital
Novel treatments and clinical trials for myeloma
Use of novel laboratory testing methods
Fellow of Royal College Physicians
Academic Clinical Fellowship in Haematology
Cancer Research UK Clinical Research Fellowship for PhD at Cambridge University
American Society of Hematology Abstract Achievement Award
Sive J, Cuthill K et al. British Society of Haematology. Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. Br J Haematol. 2021 Apr;193(2):245-268
Richards H, Chavda SJ, Wilson W, Camilleri M, Cohen O, Horder J, Newrick F, Papanikolaou X, Sive J, Lee L, Popat R, Wechalekar A, Kyriakou C, Yong K, Rabin N. Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience. Leuk Lymphoma. 2021 Aug 4:1-4
Camilleri M, McGrath T, Wilson W, Ings SJ, Horder J, Newrick F, Sive J et al., Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients. Leuk Lymphoma. 2021 Jun 24:1-4
Jurgensen-Rauch A, Gibbs S, Farrell M, Aries J, Grantham M, Eccersley L, Gribben J, Hallam S, Oakervee H, Cavenagh J, Davies J, Sive J. Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients - a single centre experience. Br J Haematol. 2021 Apr;193(2):420-423
High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry.Sayar Z, Weatherill A, Keddie S, Sive J, Lunn MP, Thomas M, D'Sa S.Blood Adv. 2020 May 26;4(10):2139-2142
Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations.Chavda SJ, Pocock R, Cheesman S, Lee KM, Dowling E, Marks DJB, Kyriakou C, Lee L, Sive J, Wechalekar A, Rabin N, Yong K, Popat R. Br J Haematol. 2020 Jun 14.
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival. Chin M, Sive JI, Allen C, Roddie C, Chavda SJ, Smith D, Blombery P, Jones K, Ryland GL, Popat R, Rismani A, D'Sa S, Rabin N, Gale RE, Yong KL. Blood Cancer J. 2017 Sep 15;7(9):
Global hypomethylation in myeloma is associated with poor prognosis. Sive JI, Feber A, Smith D, Quinn J, Beck S, Yong K. Br J Haematol. 2016 Feb;172(3):473-5.
Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience. Sive J, Ardeshna KM, Cheesman S, le Grange F, Morris S, Nicholas C, Peggs K, Statham P, Goldstone AH. Leuk Lymphoma. 2012 Dec;53(12):2397-404.
Haematological Cancer. Sive JI and Foggo V in Kumar and Clark's Clinical Medicine (10th Edition). Elsevier, London 2020.
Courses offered to GPs
Common haematology referrals
Introduction to myeloma
- FRCPath Royal College of Pathologists 2013
- PhD University of Cambridge 2016
- MRCP Royal College of Physicians 2005
- FRCP Royal College of Physicians 2021
- MBChB University of Manchester 2002
Reference number 6054442
Professional bodies (positions held - last 3 yrs)
- Consultant Haematologist University College London Hospital 2019
Affiliations / memberships
British Society for Haematology
UK Myeloma Forum
UK Myeloma Research Alliance
- Leaders in Oncology Care
- 14:30 - 19:00
- 020 7317 2631
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (>50)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (5-50)
Diagnostic aspiration and trephine biopsy of bone marrow, including analysis - (1-5)
Intravenous infusion (as sole procedure) - (1-5)